Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20327817 | 0.84 | ALDH1A1 (0.62) | KMT2AGAAHTTALDH1A1CA12 | |
| SCHEMBL9577239 | 0.83 | SIGMAR1 (0.68) | SIGMAR1KMT2AGAAALDH1A1CA1 | |
| SCHEMBL27896976 | 0.83 | HTT (0.72) | KMT2AGAAHTTALDH1A1CA12 | |
| SCHEMBL3704958 | 0.83 | CA12 (0.71) | KMT2AHTTALDH1A1NAMPTCA12 | |
| SCHEMBL26787768 | 0.83 | ALDH1A1 (0.64) | KMT2AGAAHTTALDH1A1CA12 | |
| SCHEMBL5649673 | 0.83 | KMT2A (0.57) | KMT2AHTTALDH1A1RAB9ANAMPT | |
| SCHEMBL6568086 | 0.82 | ALDH1A1 (0.61) | KMT2AHTTALDH1A1NAMPT | |
| SCHEMBL2934786 | 0.82 | ALDH1A1 (0.67) | SIGMAR1GAAALDH1A1CA1CA2 | |
| SCHEMBL3019231 | 0.80 | SIGMAR1 (0.70) | SIGMAR1GAAALDH1A1CA12CA1 | |
| SCHEMBL28719400 | 0.80 | MMP2 (0.56) | KMT2AGAAHTTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173014-A1 | Nobel compounds having selective inhibiting effect at gsk3 | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | claimed |
| EP-1575939-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | claimed |
| WO-2004055006-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | WO | claimed |
| US-20100081660-A1 | Novel Compounds Having Selective Inhibiting Effect at GSK3 | BERG STEFAN | 2010-04-01 | — | — | US | disclosed |
| US-7595319-B2 | Useful for the prevention and/or treatment of cognitive disorders; 3-Amino-N-(3-nitrophenyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide, for example | ASTRAZENECA AB (SE) | 2009-09-29 | — | — | US | disclosed |
| US-20060173014-A1 | Nobel compounds having selective inhibiting effect at gsk3 | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | disclosed |
| EP-1575939-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004055006-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081660-A1 | Novel Compounds Having Selective Inhibiting Effect at GSK3 | GSK3B, GSK3A, GSKIP | SIGMAR1 2872/4885KMT2A 1492/4885GAA 967/4885 |
| US-20060173014-A1 | Nobel compounds having selective inhibiting effect at gsk3 | GSK3B, GSK3A, GSKIP | SIGMAR1 2961/4885KMT2A 1300/4885GAA 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.